Please use this identifier to cite or link to this item:
|Title:||Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib||Authors:||Teng, W.C.
|Issue Date:||Oct-2010||Citation:||Teng, W.C., Oh, J.W., New, L.S., Wahlin, M.D., Nelson, S.D., Ho, H.K., Chan, E.C.Y. (2010-10). Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib. Molecular Pharmacology 78 (4) : 693-703. ScholarBank@NUS Repository. https://doi.org/10.1124/mol.110.065839||Abstract:||Fatalities stemming from hepatotoxicity associated with the clinical use of lapatinib (Tykerb), an oral dual tyrosine kinase inhibitor (ErbB-1 and ErbB-2) used in the treatment of metastatic breast cancer, have been reported. We investigated the inhibition of CYP3A4 by lapatinib as a possible cause of its idiosyncratic toxicity. Inhibition of CYP3A4 was time-, concentration-, and NADPH-dependent, with kinact = 0.0202 min-1 and Ki = 1.709 μM. The partition ratio was approximately 50.9. Addition of GSH did not affect the rate of inactivation. Testosterone protected CYP3A4 from inactivation by lapatinib. The characteristic Soret peak associated with a metabolite-intermediate complex was not observed for lapatinib during spectral difference scanning. However, reduced carbon monoxide (CO)-difference spectroscopy did reveal a 43% loss of the spectrally detectable CYP3A4-CO complex in the presence of lapatinib. Incubation of either lapatinib or its dealkylated metabolite with human liver microsomes in the presence of GSH resulted in the formation of a reactive metabolite (RM)-GSH adduct derived from the O-dealkylated metabolite of lapatinib. In addition, coincubation of lapatinib with ketoconazole inhibited the formation of the RM-GSH adduct. In conclusion, we demonstrated for the first time that lapatinib is a mechanism-based inactivator of CYP3A4, most likely via the formation and further oxidation of its O-dealkylated metabolite to a quinoneimine that covalently modifies the CYP3A4 apoprotein and/or heme moiety. Copyright © 2010 The American Society for Pharmacology and Experimental Therapeutics.||Source Title:||Molecular Pharmacology||URI:||http://scholarbank.nus.edu.sg/handle/10635/106127||ISSN:||0026895X||DOI:||10.1124/mol.110.065839|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Feb 18, 2020
WEB OF SCIENCETM
checked on Feb 18, 2020
checked on Feb 15, 2020
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.